A case-control study of non-alcoholic fatty liver disease in breast cancer

Medical Oncology

Volumn 24, Issue 4, 2007, Pages 367-371

  Bilici, Ahmet ^a   Ozguroglu, Mustafa ^a   Mihmanli, Ismail ^a   Turna, Hande ^a   Adaletli, Ibrahim ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; NAFLD; Tamoxifen and chemotherapy

Indexed keywords

AMINOTRANSFERASE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; ECHOGRAPHY; ENZYME BLOOD LEVEL; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; L-LACTATE DEHYDROGENASE; MIDDLE AGED; RISK FACTORS;

EID: 36248987256     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0034-8     Document Type: Article

References (38)

1. Brunt EM. Non-alcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16
2. Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998;351:725
3. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, Inomata T, Enzan H, Onishi S, Yoshida S. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 2000;7:1299-304
4. Hamada N, Ogawa Y, Saibara T, Murata Y, Kariya S, Nishioka A, Terashima M, Inomata T, Yoshida S. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Int J Oncol 2000;17:1119-23
5. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41
6. Peppercorn PD, Reznek RH, Wilson P, et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998;77:2008-11
7. Sorensen P, Edal AL, Madsen EL, et al. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer 1995;75:2592-6
8. Norum J. 5-Fluorouracil/levomisole induced intrahepatic fat infiltration imitating liver metastasis. Acta Oncol 1995;34:971-2
9. Cortez-Pinto H, Baptista A, Camilo ME, et al. Tamoxifen-associated steatohepatitis-report of three cases. J Hepatol 1995;23:95-7
10. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. Ann Int Med 1995;123:236
11. Cai Q, Bensen M, Greene R, et al. Tamoxifen-induced transient multifocal hepatic fatty infiltration. Am J Gastroenterol 2000;95:277-9
12. Floren LC, Hebert MF, Venook AP, et al. Tamoxifen in liver disease: potential excerbation of dysfunction. Ann Oncol 1998;9:1123-6
13. Ahmed MH, Osman KA. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist. Breast Cancer Res Treat 2006;97:223-4
14. Elefsinitios IS, Pantazis KD, Ilias A, Pallis L, Mariolis A, Glynou I, Kada H, Moulakasis A. Tamoxifen induced hepatotoxicity in breast cancer patients with preexisting liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol 2004;16:593-8
15. Coskun U, Toruner FB, Gunel N. Tamoxifen therapy and hepatic steatosis. Neoplasma 2002;49:61-4
16. Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG. Relationship between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disorb 2001;25:296-8
17. Nemoto Y, Saibara T, Ogawa Y, Zhang T, Xu N, Ono M, Akisawa N, Iwasaki S, Maeda T, Onishi S. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Intern Med 2002;41:345-50.
18. Murata Y, Ogawa Y, Saibara T, Nishioka A, Takeuchi N, Kariya S, Onishi S, Yoshida S. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Oncol Rep 2003;97-100
19. Less WR. Ultrasound of liver and spleen. In: Sutton D, editors. A textbook of radiology and imaging. London: Churchill Livingstone; 1993. p. 457-72
20. Matteoni CA, Younossi ZM , Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonoalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9
21. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26
22. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Terri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-9
23. Nonomura A, Mizukami Y, Unoura M, et al. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 1992;27:521-8
24. Sheth SG, Gordon FD, Chopra S. Non-alcoholic steatohepatitis. Ann Intern Med 1997;126:137-45
25. James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identiy and importance. J Hepatol 1998;29:495-501
26. Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR, MacSween RN. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999;353:36-7
27. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in Obesity: a reversible condition. Acta Med Scand 1986;220:83-8
28. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-7
29. Andersen T, Gluud C. Liver morphology in morbid obesity: a literature study. Int J Obes 1984;8:97-106
30. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo clin Proc 2000;75:733-9
31. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F, Croce LS, Paoletti S, de Bernard B, Tiribelli C, Dalla Palma L. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997;27:108-13
32. Scatarige JC, Scott WW, Donovan PJ, Siegelman SS, Sanders RC. Fatty infiltration of the ultrasonographic and computed tomographic correlation. J Ultrasound Med 1984;3:9-14
33. Davies RJ, Saverymuttu SH, Fallowfield M. Paradoxical lack of ultrasound attenuation with gross fatty change in the liver. Clin Radiol 1991;43:393
34. Akpunonu BE, Federman DJ. Nonalcoholic sreatohepatitis. Ann Int Med 1997;127:410-1
35. Blackburn AM, Amiel SA, Millis RR, Rubens RD. Tamoxifen and liver damage. Br Med J 1984;289:288
36. DeGregorio MW, Wiebe VJ, Venook AP, Holleran WM. Elevated plasma tamoxifen levels in a patient with liver obstruction. Cancer Chemother Pharmacol 1989;23:194-5
37. Windler EE, Kovanen PT, Chao YS, Brown MS, Hovel RJ, Goldstein JL. The estradiol stimulated lipoprotein receptor of rat liver: a binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem 1980;255:10464-71
38. Staels B, Auwerx J, Chan L, van Tol A, Rosseneu M, Verhoeven G. Influence of devolepment, estrogens and food intake on apolipoprotein A-I, A-II and E in mRNA in rat liver and intestine. J Lipid Res 1989;30:1137-45